|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"park k"
Showing items 21-30 of 66 (7 Page(s) Totally)
<< < 1 2 3 4 5 6 7 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
|
Wu Y.-L.;Cheng Y.;Zhou J.;Lu S.;Zhang Y.;Zhao J.;Kim D.-W.;Soo R.A.;Kim S.-W.;Pan H.;Chen Y.-M.;Chian C.-F.;Liu X.;Tan D.S.W.;Bruns R.;Straub J.;Johne A.;Scheele J.;Park K.;Chih-Hsin Yang;Liu Z.;Chen X.;Wang M.;Yu S.;Zhang H.;Fang J.;Li W.;Yang C.-H.;Chang G.-C.;Hsia T.-C.;Yang C.-T.;Wang C.-C.;Cho B.C.;Lee K.H.;Kim Y.-C.;An H.J.;Woo I.S.;Cho J.Y.;Shin S.W.;Lee J.-S.;Kim J.-H.;Yoo S.S.;Kato T.;Shinagawa N.;Tan S.W.D.;Ngo L.S.-M.;Ratnavelu K.;Ahmad A.R.;Liam C.K.;De Marinis F.;Tassone P.;Molla A.I.;Calles Blanco A.;Lazaro Quintela M.E.;Felip Font E.;Dingemans A.-M.;Bui L.; Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. |
| 臺大學術典藏 |
2021-04-23T05:56:25Z |
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non�Vsmall Cell Lung Cancer
|
Yu H.A.;Paz-Ares L.G.;Chih-Hsin Yang;Lee K.H.;Garrido P.;Park K.;Kim J.-H.;Lee D.H.;Mao H.;Wijayawardana S.R.;Gao L.;Hozak R.R.;Chao B.H.;Planchard D.; Yu H.A.; Paz-Ares L.G.; CHIH-HSIN YANG; Lee K.H.; Garrido P.; Park K.; Kim J.-H.; Lee D.H.; Mao H.; Wijayawardana S.R.; Gao L.; Hozak R.R.; Chao B.H.; Planchard D. |
| 臺大學術典藏 |
2021-04-23T05:56:23Z |
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial
|
Park K.;?Zg?Ro?Lu, Mustafa;Vansteenkiste J.;Spigel D.;Chih-Hsin Yang;Bajars M.;Ruisi M.;Manitz J.;Barlesi F.; Park K.; ?zg?ro?lu, Mustafa; Vansteenkiste J.; Spigel D.; CHIH-HSIN YANG; Bajars M.; Ruisi M.; Manitz J.; Barlesi F. |
| 中山醫學大學 |
2021 |
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
|
Park, K; Janne, PA; Kim, DW; Han, JY; Wu, MF; Lee, JS; Kang, JH; Lee, DH; Cho, BC; Yu, CJ; Pang, YK; Felip, E; Kim, H; Baek, E; Noh, YS |
| 中山醫學大學 |
2021 |
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation
|
Park, K; Chang, GC; Curigliano, G; Lim, WT; Soo, RA; Molina-Vila, MA; Cattan, V; Darville, H; Gandossi, E; Smutna, V; Sudey, I; Viteri, S |
| 中山醫學大學 |
2021 |
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
|
Chang, GC; Lam, DCL; Tsai, CM; Chen, YM; Shih, JY; Aggarwal, S; Wang, SH; Kim, SW; Kim, YC; Wahid, I; Li, RB; Lim, DWT; Sriuranpong, V; Chan, RTT; Lorence, RM; Carriere, P; Raabe, C; Cseh, A; Park, K |
| 國立成功大學 |
2021 |
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
|
Park, K.;Tan, D.S.W.;Su, W.-C.;Cho, B.C.;Kim, S.-W.;Lee, K.H.;Wang, C.-C.;Seto, T.;Huang, D.C.-L.;Jung, H.H.;Hsu, M.-C.;Bogenrieder, T.;Lin, C.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:40Z |
East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL)
|
Orlando M.; Puri T.; Alexandris E.; Lee P.; Zimmermann A.H.; Cho E.K.; Kang J.-H.; JIN-YUAN SHIH; Kim J.-H.; Park K. |
| 臺大學術典藏 |
2020-08-13T06:33:24Z |
The relevance of docetaxel-related febrile neutropenia to patient-reported symptoms and the quality of life in Japanese, East Asian (Korean, Taiwanese), and Non-east asian patients based on post-hoc analyses of two randomized clinical trials of docetaxel with and without anti-angiogenic agent in advanced non-small cell lung cancer after progression on platinum-based chemotherapy
|
Inoue A.; Omori Y.;Enatsu S.;Brnabic A.J.M.;Rajan N.;Jin-Yuan Shih;Kim J.-H.;Park K.;Inoue A.; Omori Y.; Enatsu S.; Brnabic A.J.M.; Rajan N.; JIN-YUAN SHIH; Kim J.-H.; Park K. |
| 臺大學術典藏 |
2020-05-26T09:27:18Z |
Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in east asian patients with advanced non-small cell lung cancer: Results of an exploratory subgroup analysis of a phase III trial
|
Chih-Hsin Yang;Simms L;Park K;Lee J.S;Scagliotti G;Orlando M.; CHIH-HSIN YANG; Simms L; Park K; Lee J.S; Scagliotti G; Orlando M. |
Showing items 21-30 of 66 (7 Page(s) Totally)
<< < 1 2 3 4 5 6 7 > >>
View [10|25|50] records per page
|
